Restaging After Neo-Adjuvant Chemoradiotherapy for N2 Non–Small Cell Lung Cancer - 23/08/11
, Ayesha S. Bryant, MSPH, MD b
Corresponding author.Abstract |
Recent studies have shown that patients who are down-staged via neoadjuvant therapy and undergo resection have a significant increased 5-year survival rate (as high as 40%–50%) when compared with patients who have residual N2 disease. The identification of patients who are N2 negative after the completion of their neoadjuvant therapy is a critical component of proper patient selection for thoracotomy. Some may even argue that it is a necessary step before resection. In this article we review the best ways to restage patients with N2 disease after they have completed their neoadjuvant therapy.
Le texte complet de cet article est disponible en PDF.Plan
Vol 18 - N° 4
P. 417-421 - novembre 2008 Retour au numéro
Article précédent
- Neoadjuvant Therapy for Resectable Non–Small Cell Lung Cancer with Mediastinal Lymph Node Involvement
- Brandon H. Tieu, Rachel E. Sanborn, Charles R. Thomas
- Adjuvant Therapy for Non–Small Cell Lung Cancer with Mediastinal Nodal Involvement
- Rachel E. Sanborn, Brian E. Lally
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?